Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan 11:10:1280547.
doi: 10.3389/fcvm.2023.1280547. eCollection 2023.

SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis

Qing Zhang  1 , Zhiwen Deng  1 , Tudi Li  1 , Kaitong Chen  1 , Zhihuan Zeng  1
Affiliations
Review

SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis

Qing Zhang et al. Front Cardiovasc Med. .

Abstract

Coronary heart disease is a narrowing or obstruction of the vascular cavity caused by atherosclerosis of the coronary arteries, which leads to myocardial ischemia and hypoxia. At present, percutaneous coronary intervention (PCI) is an effective treatment for coronary atherosclerotic heart disease. Restenosis is the main limiting factor of the long-term success of PCI, and it is also a difficult problem in the field of intervention. Sodium-glucose cotransporter 2 (SGLT2) inhibitor is a new oral glucose-lowering agent used in the treatment of diabetes in recent years. Recent studies have shown that SGLT2 inhibitors can effectively improve the prognosis of patients after PCI and reduce the occurrence of restenosis. This review provides an overview of the clinical studies and mechanisms of SGLT2 inhibitors in the prevention of restenosis, providing a new option for improving the clinical prognosis of patients after PCI.

Keywords: AMI—acute myocardial infarction; ASCVD-atherosclerotic cardiovascular disease; SGLT2 inhibitor; coronary heart disease; restenosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Pathophysiology of restenosis. Endothelial injury, inflammation, and neointima formation are the main causes of restenosis.
Figure 2
Figure 2
SGLT2 inhibitors can improve the prognosis of patients after PCI by improving glucose and lipid metabolism, inhibiting inflammatory response and oxidative stress, and inhibit neointima formation.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Tian Y, Deng P, Li B, Wang J, Li J, Huang Y, et al. Treatment models of cardiac rehabilitation in patients with coronary heart disease and related factors affecting patient compliance. Rev Cardiovasc Med. (2019) 20(1):27–33. 10.31083/j.rcm.2019.01.53 - DOI - PubMed
    1. Doenst T, Haverich A, Serruys P, Bonow RO, Kappetein P, Falk V, et al. PCI And CABG for treating stable coronary artery disease: JACC review topic of the week. J Am Coll Cardiol. (2019) 73(8):964–76. 10.1016/j.jacc.2018.11.053 - DOI - PubMed
    1. Shan L, Saxena A, McMahon R. A systematic review on the quality of life benefits after percutaneous coronary intervention in the elderly. Cardiology. (2014) 129(1):46–54. 10.1159/000360603 - DOI - PubMed
    1. Konijnenberg LSF, Damman P, Duncker DJ, Kloner RA, Nijveldt R, van Geuns RM, et al. Pathophysiology and diagnosis of coronary microvascular dysfunction in ST-elevation myocardial infarction. Cardiovas Res. (2020) 116(4): 787–805. 10.1093/cvr/cvz301 - DOI - PMC - PubMed
    1. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. (2015) 36(19):1163–70. 10.1093/eurheartj/ehu505 - DOI - PubMed